A Study to Evaluate the Efficacy and Safety of CREZET Tablet

Exclusion Criteria

• •1. A person who is prohibited from administering according to the permission of the Crezet definition
• •* Patients who overreact to the principal or component of the Crezet definition
• •* Patients with active liver disease or patients with persistent high symptoms of serum aminotransferase levels
• •* a patient with a muscle disease
• •* a patient administered in combination with a cyclosporine-med
• •* Patients with severe renal failure (Creatinine Clearance (CLcr) \< 30 mL/min)
• •* Women and lactating women who may be pregnant or pregnant
• •* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• •2. A person who has a history of taking Crezet tablets within three months of the date of registration
• •3. A person who is deemed inappropriate to participate in this observational study based on the judgment of investigator.